Jolita Badarienė1, Egidija Rinkūnienė2, Vytautas Kasiulevičius3, Giedrė Smaliukaitė4, Viktorija Selskaitė4, Jūratė Barysienė2, Vilma Dženkevičiūtė2,3. 1. Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania. jolita.badariene@santa.lt. 2. Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania. 3. Clinic of Internal, Family Medicine and Oncology, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania. 4. Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Abstract
INTRODUCTION: Lithuania has one of the highest mortality rates from coronary heart disease (CHD) among European countries. Most CHD are preventable, but when they occur, the management of these patients is important in secondary prevention. The purpose of the present analysis was to describe the demographics, clinical profile, and contemporary management of patients with stable CHD in the Lithuanian population and to compare data with other Central Eastern European countries. METHODS: CLARIFY (prospective observational longitudinal registry of patients with stable CHD) is an international cohort study in outpatients with stable CHD. Treated outpatients with established CHD from the CLARIFY registry in Lithuania (214 patients) were compared with those from the rest of Central Eastern Europe (2794 patients). RESULTS: Lithuanian patients were younger (p = 0.0275), had a higher body mass index (p = 0.0003), and more frequently received treatment for hypertension (p < 0.0001). Prevalence of dyslipidemia (p < 0.0001) was higher in Lithuanian patients but a smaller group of people had diabetes (p < 0.0001). The total cholesterol (p < 0.0001), low-density lipoprotein cholesterol (p < 0.0001), and blood pressure (p < 0.0001) were higher in the Lithuanian population. A smaller proportion of Lithuanian patients were physically inactive, and the majority of patients in Lithuania were engaged in light physical activity compared with Central Eastern European patients (p = 0.0018). CONCLUSION: The data analysis shows that management of hypertension, dyslipidemia, smoking, and obesity in patients with CHD in Lithuania is insufficient and needs further improvement.
INTRODUCTION: Lithuania has one of the highest mortality rates from coronary heart disease (CHD) among European countries. Most CHD are preventable, but when they occur, the management of these patients is important in secondary prevention. The purpose of the present analysis was to describe the demographics, clinical profile, and contemporary management of patients with stable CHD in the Lithuanian population and to compare data with other Central Eastern European countries. METHODS: CLARIFY (prospective observational longitudinal registry of patients with stable CHD) is an international cohort study in outpatients with stable CHD. Treated outpatients with established CHD from the CLARIFY registry in Lithuania (214 patients) were compared with those from the rest of Central Eastern Europe (2794 patients). RESULTS: Lithuanian patients were younger (p = 0.0275), had a higher body mass index (p = 0.0003), and more frequently received treatment for hypertension (p < 0.0001). Prevalence of dyslipidemia (p < 0.0001) was higher in Lithuanian patients but a smaller group of people had diabetes (p < 0.0001). The total cholesterol (p < 0.0001), low-density lipoprotein cholesterol (p < 0.0001), and blood pressure (p < 0.0001) were higher in the Lithuanian population. A smaller proportion of Lithuanian patients were physically inactive, and the majority of patients in Lithuania were engaged in light physical activity compared with Central Eastern European patients (p = 0.0018). CONCLUSION: The data analysis shows that management of hypertension, dyslipidemia, smoking, and obesity in patients with CHD in Lithuania is insufficient and needs further improvement.
Authors: Roberto Ferrari; Hélène Abergel; Ian Ford; Kim M Fox; Nicola Greenlaw; Ph Gabriel Steg; Dayi Hu; Michal Tendera; Jean-Claude Tardif Journal: Int J Cardiol Date: 2012-09-15 Impact factor: 4.164
Authors: José R Banegas; Esther López-García; Jean Dallongeville; Eliseo Guallar; Julian P Halcox; Claudio Borghi; Elvira L Massó-González; Francisco J Jiménez; Joep Perk; Philippe Gabriel Steg; Guy De Backer; Fernando Rodríguez-Artalejo Journal: Eur Heart J Date: 2011-04-06 Impact factor: 29.983
Authors: Ph Gabriel Steg; Nicola Greenlaw; Jean-Claude Tardif; Michal Tendera; Ian Ford; Stefan Kääb; Hélène Abergel; Kim M Fox; Roberto Ferrari Journal: Eur Heart J Date: 2012-08-26 Impact factor: 29.983
Authors: Emmanuel Sorbets; Nicola Greenlaw; Roberto Ferrari; Ian Ford; Kim M Fox; Jean-Claude Tardif; Michal Tendera; Philippe Gabriel Steg Journal: Clin Cardiol Date: 2017-05-31 Impact factor: 2.882